Drugs / Lentiviral vector transduced CD34+ cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03601286 | Dec 2018 → Aug 2026 overdue | combined immunodeficiency, X-linked | Great Ormond Street Hospital for Children NHS Foundation Trust | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lentiviral vector transduced CD34+ cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03601286 ↗ |
| Action | Restore | “introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells)” NCT03601286 ↗ |
| Route | Other | “The gene corrected cells are then transplanted back into the patient.” NCT03601286 ↗ |
| Target | IL2RG | “introduction a normal copy of the IL2RG gene” NCT03601286 ↗ |